A detailed history of Advisor Group Holdings, Inc. transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 6,176 shares of VYGR stock, worth $35,697. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,176
Previous 4,461 38.44%
Holding current value
$35,697
Previous $35,000 2.86%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.77 - $9.27 $9,895 - $15,898
1,715 Added 38.44%
6,176 $36,000
Q2 2024

Aug 13, 2024

SELL
$7.42 - $10.54 $41,811 - $59,392
-5,635 Reduced 55.81%
4,461 $35,000
Q1 2024

May 10, 2024

BUY
$7.15 - $10.84 $31,917 - $48,389
4,464 Added 79.26%
10,096 $93,000
Q4 2023

Feb 12, 2024

BUY
$6.28 - $8.81 $9,891 - $13,875
1,575 Added 38.82%
5,632 $47,000
Q3 2023

Nov 13, 2023

BUY
$7.55 - $11.25 $9,143 - $13,623
1,211 Added 42.55%
4,057 $31,000
Q2 2023

Aug 10, 2023

SELL
$6.94 - $13.99 $4,885 - $9,848
-704 Reduced 19.83%
2,846 $32,000
Q1 2023

May 12, 2023

BUY
$6.0 - $10.78 $2,700 - $4,851
450 Added 14.52%
3,550 $27,000
Q4 2022

Feb 10, 2023

BUY
$4.94 - $6.61 $2,964 - $3,966
600 Added 24.0%
3,100 $18,000
Q2 2022

Aug 10, 2022

SELL
$4.82 - $10.09 $2,410 - $5,045
-500 Reduced 16.67%
2,500 $15,000
Q1 2022

May 04, 2022

BUY
$2.75 - $9.44 $8,250 - $28,320
3,000 New
3,000 $22,000
Q3 2020

Nov 12, 2020

SELL
$10.01 - $13.75 $1,191 - $1,636
-119 Closed
0 $0
Q1 2020

May 18, 2020

BUY
$6.8 - $14.66 $809 - $1,744
119 New
119 $1,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $223M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.